Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.617.3ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
B.1.617.3ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.617.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.109 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.109 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.109 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.109 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.4.2.2 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.4.2.2 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.4.2.2 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.4.2.2 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.4.2.3 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.4.2.3 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.4.2.3 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.4.2.3 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.4.8 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.4.8 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.4.8 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.4.8 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.617.1 (Kappa)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
B.1.617.1 (Kappa)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
B.1.617.1 (Kappa)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
B.1.617.1 (Kappa)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.4.3 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.4.3 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.4.3 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.4.3 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.46.5 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.46.5 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.46.5 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.46.5 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.4.1 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.4.1 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.4.1 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.4.1 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
P.1.16 (Gamma)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
P.1.16 (Gamma)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
P.1.16 (Gamma)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
P.1.16 (Gamma)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.10.3ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
BA.2.10.3ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
BA.2.10.3ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
BA.2.10.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.4.5 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.4.5 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.4.5 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
AY.4.5 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.34.1 (Delta)ORF1abPasteur-ORF1ab-2CTGGTCAAGGTTAATATAGG20401418614167R-18348.8France
AY.34.1 (Delta)ENiu-ETTCTTGCTTTCGTGGTATTC20402630326322F-19913.4China
AY.34.1 (Delta)ENiu-ECACGTTAACAATATTGCAGC20402639126372R-20723.8China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used